Skip to main content

Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders

Guest Editors:
Charlotte TeunissenAmsterdam UMC, the Netherlands
Everard (Jort) VijverbergAmsterdam UMC, the Netherlands

Submission Status: Open   |   Submission Deadline: 31 December 2023

Alzheimer's Research & Therapy is calling for submissions to our Collection on Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders.

About the collection

The scientific field of neurodegenerative dementias has made significant progress over the last two decades. The diagnosis for these progressive neurodegenerative diseases is increasingly shifting from syndromal, based on signs and symptoms, to a biological construct based on the pathological hallmarks. For Alzheimer's disease (AD) it is amyloid β deposition, pathologic tau, neurodegeneration, and it is expected that analysis of alfa-synuclein (e.g. by aggregating assays) can contribute to an accurate diagnosis and to define progression and treatment effects. Furthermore, numerous genetic risk factors have been identified providing further insight into the pathways underpinning dementias.

Analogous to this significant progress in making an accurate diagnosis and a better understanding in dementia disorders, the drug development landscape for disease modifying therapies also grows. Especially in AD, amyloid-targeting therapies are now showing potential, while it is clear that multitarget interventions are probably needed to better silence these diseases. Moreover, drugs against targets that play a key role in several neurodegenerative diseases can be applied across diseases.

  1. Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ ol...

    Authors: Christopher H. van Dyck, Adam P. Mecca, Ryan S. O’Dell, Hugh H. Bartlett, Nina G. Diepenbrock, Yiyun Huang, Mary E. Hamby, Michael Grundman, Susan M. Catalano, Anthony O. Caggiano and Richard E. Carson
    Citation: Alzheimer's Research & Therapy 2024 16:20
  2. Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the initial...

    Authors: Jie Wang, Yingfang He, Xing Chen, Lin Huang, Junpeng Li, Zhiwen You, Qi Huang, Shuhua Ren, Kun He, Roger Schibli, Linjing Mu, Yihui Guan, Qihao Guo, Jun Zhao and Fang Xie
    Citation: Alzheimer's Research & Therapy 2024 16:9
  3. Recently, single-nucleus RNA-seq (snRNA-seq) analyses have revealed important cellular and functional features of Alzheimer's disease (AD), a prevalent neurodegenerative disease. However, our knowledge regardi...

    Authors: Andi Liu, Brisa S. Fernandes, Citu Citu and Zhongming Zhao
    Citation: Alzheimer's Research & Therapy 2024 16:3
  4. Alzheimer’s disease (AD) is characterized by cognitive dysfunction and amyloid plaques composed of the amyloid-beta peptide (Aβ). APOE is the greatest genetic risk for AD with APOE4 increasing risk up to ~ 15-fol...

    Authors: Ana C. Valencia-Olvera, Deebika Balu, Shreya Bellur, Thomas McNally, Yaseen Saleh, Don Pham, Shivesh Ghura, Jason York, Jan O. Johansson, Mary Jo LaDu and Leon Tai
    Citation: Alzheimer's Research & Therapy 2023 15:216
  5. NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, ...

    Authors: Saily Sosa, Giosmany Bringas, Nelky Urrutia, Ana Ivis Peñalver, Danay López, Evelio González, Ana Fernández, Zenaida Milagros Hernández, Ariel Viña, Yamile Peña, Juan Felipe Batista, Carmen Valenzuela, Kalet León, Tania Crombet, Teresita Rodríguez and Leslie Pérez
    Citation: Alzheimer's Research & Therapy 2023 15:215
  6. The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...

    Authors: Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2023 15:170
  7. Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...

    Authors: Daniele Altomare, Alberto Benussi, Valentina Cantoni, Enrico Premi, Jasmine Rivolta, Chiara Cupidi, Alessandro Martorana, Emiliano Santarnecchi, Alessandro Padovani, Giacomo Koch and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2023 15:155
  8. Little is known about the associations of midlife- and late life-initiated walking with Alzheimer’s disease (AD)-related cognitive decline in humans. We aimed to investigate whether high-intensity, prolonged, ...

    Authors: Young Min Choe, Guk-Hee Suh, Boung Chul Lee, Ihn-Geun Choi, Hyun Soo Kim, Jong Wan Kim, Jaeuk Hwang, Dahyun Yi and Jee Wook Kim
    Citation: Alzheimer's Research & Therapy 2023 15:143

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.